| 產品編號 | bs-1451R |
| 英文名稱 | Rabbit Anti-PLA2G7 antibody |
| 中文名稱 | 脂蛋白磷脂酶A2抗體 |
| 別 名 | Lp-PLA2; PAFAH; lipoprotein-associated phospholipase A2; Platelet-activating factor acetylhydrolase; Lipoprotein-associated phospholipaseA2 (Lp-PLA2); PAF acetylhydrolase; PAF 2-acylhydrolase; LDL-associated phospholipase A2; LDL-PLA(2); 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase; PAFA_HUMAN. 脂蛋白相關磷脂酶A2; |
 |
Specific References (4) | bs-1451R has been referenced in 4 publications.
[IF=3.71] Rosing, Katharina, et al. Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis. 2013 Sep;230(1):164-70. WB ; Human.
[IF=2.93] Wang, Gangqi, et al. "Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NF [kgr] B pathways." Scientific Reports 4 (2014). WB ; Human.
[IF=2.1] Han et al. Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways. (2015) Biol.Open. 4:661-5 WB ; Porcine.
[IF=0] Wihastuti TA et al. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2. J Basic Clin Physiol Pharmacol. 2020 Feb 7;30(6). IHC ; Rat.
|
| 研究領域 | 心血管 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat (predicted: Dog) |
| 產品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 48kDa |
| 細胞定位 | 細胞外基質 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PAFAH: 301-441/441 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
This gene encodes platelet-activating factor acetylhydrolase isoform 2, a single-subunit intracellular enzyme that catalyzes the removal of the acetyl group at the SN-2 position of platelet-activating factor (identified as 1-O-alkyl-2-acetyl -sn-glyceryl-3-phosphorylcholine). However, this lipase exhibits a broader substrate specificity than simply platelet activating factor. Two other isoforms of intracellular platelet-activating factor acetylhydrolase exist, and both are multi-subunit enzymes. Additionally, there is a single-subunit serum isoform of this enzyme. Function: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Subcellular Location: Secreted, extracellular space. Tissue Specificity: Plasma. DISEASE: Platelet-activating factor acetylhydrolase deficiency (PAFAD) [MIM:614278]: An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. It can be associated with several disease states including inflammatory gastrointestinal disorders, asthma and atopy. Asthmatic individuals with PAFAD may manifest aggravated respiratory symptoms. Note=The disease is caused by mutations affecting the gene represented in this entry. Asthma (ASTHMA) [MIM:600807]: The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Atopic hypersensitivity (ATOPY) [MIM:147050]: A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry. Similarity: Belongs to the AB hydrolase superfamily. Lipase family. SWISS: Q13093 Gene ID: 7941 Database links: Entrez Gene: 7941 Human Omim: 601690 Human SwissProt: Q13093 Human 脂蛋白相關磷脂A2（Lp-PLA2）也稱血漿血小板激活因子乙酰水解酶，是介導氧化低密度脂蛋白引起炎癥和動脈粥樣硬化的一個關鍵性酶。 脂蛋白相關磷脂酶A2是磷脂酶A2超家族的一個成員,由成熟的巨噬細胞和淋巴細胞合成和分泌,主要與低密度脂蛋白結合,能水解低密度脂蛋白上的氧化卵磷脂,生成促炎物質溶血卵磷脂和氧化型游離脂肪酸,促進動脈粥樣硬化形成,經研究認為：抑制脂蛋白相關磷脂酶A2活性可能有抗動脈粥樣硬化的效應。 |
| 產品圖片 |
Sample:
Lung (Rat) Lysate at 40 ug
Primary: Anti-PAFAH (bs-1451R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 48 kD
Observed band size: 48 kD
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PAFAH) Polyclonal Antibody, Unconjugated (bs-1451R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (Rat liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PAFAH) Polyclonal Antibody, Unconjugated (bs-1451R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
Tissue/cell: human placenta tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-PAFAH2/Lp-PLA2 Polyclonal Antibody, Unconjugated(bs-1451R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: rat spleen tissue;4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-PAFAH2 Polyclonal Antibody, Unconjugated(bs-1451R) 1:200, overnight at 4°C; The secondary antibody was Goat Anti-Rabbit IgG, Cy3 conjugated(bs-0295G-Cy3)used at 1:200 dilution for 40 minutes at 37°C.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
